COMPARISON OF BEDSIDE AND HOSPITAL LABORATORY COAGULATION STUDIES DURING AND AFTER CORONARY INTERVENTION

被引:10
作者
BLUMENTHAL, RS
CARTER, AJ
RESAR, JR
COOMBS, V
GLOTH, ST
DALAL, J
BRINKER, JA
机构
[1] JOHNS HOPKINS UNIV,BALTIMORE,MD 21218
[2] WALTER REED ARMY MED CTR,WASHINGTON,DC 20307
来源
CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS | 1995年 / 35卷 / 01期
关键词
COAGULATION; HEPARIN; PTCA;
D O I
10.1002/ccd.1810350104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The activated clotting time is routinely used to monitor anticoagulation during coronary intervention, whereas the hospital laboratory APTT guides pre- and postprocedure heparin therapy, An optimal coagulation test far patients undergoing percutaneous revascularization would provide a rapid and accurate assessment of anticoagulation throughout a broad range of heparin therapy, We studied the relationships of the bedside whole blood APTT, ACT, and the laboratory APTT in 166 patients undergoing coronary intervation. The whole blood APTT correlated closely with the laboratory APTT (range 18-80 sec) (r = .75), whereas the ACT and laboratory APTT had only a fair correlation(r = .42). Also, the whole blood APTT demonstrated a strong correlation with the ACT throughout the range of heparin therapy for intervention (r = .81), The diagnostic accuracy of the whole blood APTT, based on the receiver operating characteristic curve, was significantly better than that for the ACT in determining the anticoagulation status. The whole blood APTT obtained by bedside monitoring provides a rapid and accurate assessment of anticoagulation throughout the range of heparin dosing associated with coronary intervention, In situations in which an adequate assessment of residual anticoagulation is necessary, the whole blood APTT is superior to the ACT and probably should be the method of choice. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 33 条
[1]   COMPARISON OF HEMOCHRON AND HEMOTEC ACTIVATED COAGULATION TIME TARGET VALUES DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [J].
AVENDANO, A ;
FERGUSON, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (04) :907-910
[2]  
Becker Richard, 1993, Journal of the American College of Cardiology, V21, p219A
[3]   PREPROCEDURAL ANTICOAGULATION DOES NOT REDUCE ANGIOPLASTY HEPARIN REQUIREMENTS [J].
BLUMENTHAL, RS ;
WOLFF, MR ;
RESAR, JR ;
COOMBS, VJ ;
BRINKER, JA .
AMERICAN HEART JOURNAL, 1993, 125 (05) :1221-1225
[4]  
BODE AP, 1993, THROM RES, V73, P285
[5]  
BOWERS J, 1993, TEX HEART I J, V20, P258
[6]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[7]  
BULL BS, 1975, J THORAC CARDIOV SUR, V69, P674
[8]   ANGIOGRAPHIC AND CLINICAL OUTCOME OF INTRACORONARY STENTING - IMMEDIATE AND LONG-TERM RESULTS FROM A LARGE SINGLE-CENTER EXPERIENCE [J].
CARROZZA, JP ;
KUNTZ, RE ;
LEVINE, MJ ;
POMERANTZ, RM ;
FISHMAN, RF ;
MANSOUR, M ;
GIBSON, CM ;
SENERCHIA, CC ;
DIVER, DJ ;
SAFIAN, RD ;
BAIM, DS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (02) :328-337
[9]  
DOUGHERTY KG, 1991, CATHET CARDIOVASAC D, V26, P260
[10]   SUBCUTANEOUS HEPARIN IN POSTANGIOPLASTY MANAGEMENT - COMPARATIVE TRIAL WITH INTRAVENOUS HEPARIN [J].
FAIL, PS ;
MANIET, AR ;
BANKA, VS .
AMERICAN HEART JOURNAL, 1993, 126 (05) :1059-1067